BioCentriq Stock

www.biocentriq.comHealthcare / BioTech & PharmaFounded: 2019

BioCentriq is a manufacturing company that works in cell therapy. The global company creates drug products with a mission to improve medical manufacturing and drug administration processes across borders. Specialties of BioCentriq include allogenic cell therapies, GMP production, cell banking, autologous cell therapies, and viral banking. BioCentriq was founded by Haro Hartounian in 2019 and is headquartered in New York, New York.

Register To Buy and Sell Shares

For more details on financing and valuation for BioCentriq, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access BioCentriq’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like BioCentriq.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

BioCentriq investors also invested in these private companies

National Institute for Innovation in Manufacturing Biopharmaceuticals

Team

Management Team

Jennifer Manning
Chief Commercial Officer
Jackie Panter
Chief Quality and Compliance Officer
Mark Broadley
Vice President of Operations
David Smith, Ph.D.
Vice President of Development
Henry Han
Senior Director, Finance
Gina Choi
Head of Human Resources

BioCentriq’s stock FAQs

plusminus

Can you buy BioCentriq’s stock?

BioCentriq is not publicly traded on NYSE or NASDAQ in the U.S. To buy BioCentriq’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell BioCentriq’s stock?

Yes, you can sell stock of a private company like BioCentriq. Forge can help you sell your BioCentriq stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus

What is BioCentriq’s stock price?

BioCentriq is a privately held company and therefore does not have a public stock price. However, you may access BioCentriq’s private market stock price with Forge Data.
plusminus

What is BioCentriq’s stock ticker symbol?

BioCentriq does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

BioCentriq Raises $29.2M in Series A Funding

BioCentriq, a Newark, NJ-based cell-based therapy contract development and manufacturing organization (CDMO), raised $29.2M in Series A funding. The backers were not disclosed. The company intends to use the funds to enhance its facilities, invest in advanced technologies, and expand its team. Led by CEO James Park, BioCentriq specializes in cell therapy contract development and manufacturing, with a track record transferring, developing, and manufacturing GMP drug product for use in clinical trials.
Updated on: Jun 24, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.